Skip to content


Antibiotic research pushed forward by use of large infrastructures

Robert Schnell is a scientist at Karolinska Institute focusing on development of novel antibiotic candidates. He has used both SciLifeLab and MAX IV laboratory infrastructures in a multifaceted project addressing the problem of infectious diseases in the context of the silent pandemic of antimicrobial resistance (AMR).